During the past few years, the establishment of immunotherapy (e.i. stimulation of the immune system to recognize and kill malignant cells) as a reliable therapeutic option to tackle cancer, has shifted the paradigm of cancer treatment. Among the different classes of cancer immunotherapies, including checkpoint inhibitor monoclonal antibodies (2018 Nobel Prize Physiology or Medicine), adoptive T cell therapies (ACTs), harboring CAR-T cells, are emerging as a revolutionary strategy to eliminate tumors.
